Exome Sequencing and the Management of Neurometabolic Disorders
Open accessThe DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Whole-exome sequencing has transformed gene discovery and diagnosis in rare diseases. Translation into disease-modifying treatments is challenging, particularly for intellectual developmental disorder. However, the exception is inborn errors of metabolism, since many of these disorders are responsive to therapy that targets pathophysiological features at the molecular or cellular level. METHODS: To uncover the genetic basis of potentially treatable inborn errors of metabolism, we combined deep clinical phenotyping (the comprehensive characterization of the discrete components of a patient's clinical and biochemical phenotype) with whole-exome sequencing analysis through a semiautomated bioinformatics pipeline in consecutively enrolled patients with intellectual developmental disorder and unexplained metabolic phenotypes. RESULTS: We performed whole-exome sequencing on samples obtained from 47 probands. Of these patients, 6 were excluded, including 1 who withdrew from the study. The remaining 41 probands had been born to predominantly nonconsanguineous parents of European descent. In 37 probands, we identified variants in 2 genes newly implicated in disease, 9 candidate genes, 22 known genes with newly identified phenotypes, and 9 genes with expected phenotypes; in most of the genes, the variants were classified as either pathogenic or probably pathogenic. Complex phenotypes of patients in five families were explained by coexisting monogenic conditions. We obtained a diagnosis in 28 of 41 probands (68%) who were evaluated. A test of a targeted intervention was performed in 18 patients (44%). CONCLUSIONS: Deep phenotyping and whole-exome sequencing in 41 probands with intellectual developmental disorder and unexplained metabolic abnormalities led to a diagnosis in 68%, the identification of 11 candidate genes newly implicated in neurometabolic disease, and a change in treatment beyond genetic counseling in 44%. (Funded by BC Children's Hospital Foundation and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“can be used to inform patient management”
From Tackling healthcare access barriers for individuals with autism from diagnosis to adulthood (2022) · cites this paper as [103]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049
dbSNP: the NCBI database of genetic variation
Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502
Kumar, P., Henikoff, S., & Ng, P. C. (2009) · Nature Protocols · doi:10.1038/nprot.2009.86 · Cited by 6,521
A general framework for estimating the relative pathogenicity of human genetic variants
Kircher, M., Witten, D. M., Jain, P., O'Roak, B. J., Cooper, G. M., & Shendure, J. (2014) · Nature Genetics · doi:10.1038/ng.2892 · Cited by 6,183
Cited by
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
“consecutively enrolled patients with unexplained intellectual developmental disorder and metabolic phenotypes, whole exome sequencing showed that >10% were attributable to genetic defects in glycosylation pathways (389), mostly hypomorphic states of genes in which complete loss would have been lethal.”
BackgroundDiagnostic Utility of Exome Sequencing for Kidney Disease
Groopman, E. E., Marasa, M., Cameron-Christie, S., Petrovski, S., Aggarwal, V. S., Milo-Rasouly, H., Li, Y., Zhang, J., Nestor, J., Krithivasan, P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1806891 · Cited by 783
Srivastava, S., Love-Nichols, J. A., Dies, K. A., Ledbetter, D. H., Martin, C. L., Chung, W. K., Firth, H. V., Frazier, T., Hansen, R. L., Prock, L., et al. (2019) · Genetics in Medicine · doi:10.1038/s41436-019-0554-6 · Cited by 695
Manickam, K., McClain, M. R., Demmer, L. A., Biswas, S., Kearney, H. M., Malinowski, J., Massingham, L. J., Miller, D., Yu, T. W., & Hisama, F. M. (2021) · Genetics in Medicine · doi:10.1038/s41436-021-01242-6 · Cited by 639
Clark, M. M., Stark, Z., Farnaes, L., Tan, T. Y., White, S. M., Dimmock, D., & Kingsmore, S. F. (2018) · npj Genomic Medicine · doi:10.1038/s41525-018-0053-8 · Cited by 619
Paediatric genomics: diagnosing rare disease in children
Wright, C. F., FitzPatrick, D. R., & Firth, H. V. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.116 · Cited by 618
DNA sequencing technologies: 2006–2016
Mardis, E. R. (2017) · Nature Protocols · doi:10.1038/nprot.2016.182 · Cited by 395
A guide for the diagnosis of rare and undiagnosed disease: beyond the exome
Marwaha, S., Knowles, J. W., & Ashley, E. A. (2022) · Genome Medicine · doi:10.1186/s13073-022-01026-w · Cited by 359
“Metabolomics For many rare unexplained metabolic disorders in children, where the causative variant was identified by ES, functional metabolomic studies have helped to uncover the disease mechanism [211–213] and even led to better disease management or treatment in some cases [24].”
BackgroundMethodA landscape of germ line mutations in a cohort of inherited bone marrow failure patients
Bluteau, O., Sebert, M., Leblanc, T., Peffault de Latour, R., Quentin, S., Lainey, E., Hernandez, L., Dalle, J.-H., Sicre de Fontbrune, F., Lengline, E., et al. (2018) · Blood · doi:10.1182/blood-2017-09-806489 · Cited by 355
Tackling healthcare access barriers for individuals with autism from diagnosis to adulthood
Malik-Soni, N., Shaker, A., Luck, H., Mullin, A. E., Wiley, R. E., Lewis, M. E. S., Fuentes, J., & Frazier, T. W. (2022) · Pediatric Research · doi:10.1038/s41390-021-01465-y · Cited by 309
Disorders affecting vitamin B6 metabolism
Wilson, M. P., Plecko, B., Mills, P. B., & Clayton, P. T. (2019) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12060 · Cited by 262
“Seizures are a major feature of disorders of the glycine-cleavage enzyme (nonketotic hyperglycinaemia), of phosphoserine aminotransferase deficiency and of mitochondrial glutamate oxalaoacetate amino transferase (GOT2) deficiency.(52,53) They WILSON ET AL.”
BackgroundPetrikin, J. E., Cakici, J. A., Clark, M. M., Willig, L. K., Sweeney, N. M., Farrow, E. G., Saunders, C. J., Thiffault, I., Miller, N. A., Zellmer, L., et al. (2018) · npj Genomic Medicine · doi:10.1038/s41525-018-0045-8 · Cited by 229
“Age at death (days; median, range) 62 (14-228) 173 (4-341) 0.”
BackgroundTebani, A., Afonso, C., Marret, S., & Bekri, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091555 · Cited by 212
“Recent studies have shown the potential of multi-omics studies to provide insightful biological inferences [64,94–99] and to help determine definitive diagnoses in the IEM field [10,11].”
BackgroundModel Organisms Facilitate Rare Disease Diagnosis and Therapeutic Research
Wangler, M. F., Yamamoto, S., Chao, H.-T., Posey, J. E., Westerfield, M., Postlethwait, J., Members of the Undiagnosed Diseases Network (UDN), Hieter, P., Boycott, K. M., Campeau, P. M., et al. (2017) · Genetics · doi:10.1534/genetics.117.203067 · Cited by 211
“…(Beaulieu et al. 2014), Care4Rare (Sawyer et al. 2016), IGNITE (Identifying Genes and Novel Therapeutics to Enhance Treatment), Omics2TreatID (Tarailo-Graovac et al. 2016), and TIDE BC (Sayson et al. 2015; Tarailo-Graovac et al. 2016), led to the identification of.300 disease genes over the…”
BackgroundWhole-Exome Sequencing in Adults With Chronic Kidney Disease: A Pilot Study
Lata, S., Marasa, M., Li, Y., Fasel, D. A., Groopman, E., Jobanputra, V., Rasouly, H., Mitrotti, A., Westland, R., Verbitsky, M., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m17-1319 · Cited by 203
“However, studies to date have focused mainly on a limited range of disorders in pediatric cohorts or on cancer in adults (7–17); thus, the clinical utility of these approaches for a broader spectrum of diseases, particularly among adults, remains unclear.”
BackgroundCoene, K. L. M., Kluijtmans, L. A. J., van der Heeft, E., Engelke, U. F. H., de Boer, S., Hoegen, B., Kwast, H. J. T., van de Vorst, M., Huigen, M. C. D. G., Keularts, I. M. L. W., et al. (2018) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0131-6 · Cited by 192
“Additionally, further integration of metabolomics and genomics with phenomics data, making use of the specialized expertise of clinicians and laboratory specialists, has shown great potential, as described by Tarailo-Graovac et al. (2016).”
BackgroundSelf-citationNGS Technologies as a Turning Point in Rare Disease Research , Diagnosis and Treatment
Fernandez-Marmiesse, A., Gouveia, S., & Couce, M. L. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666170718101946 · Cited by 180
Ramalingam, M., Kim, H., Lee, Y., & Lee, Y.-I. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00348 · Cited by 172
Genetic Modifiers and Rare Mendelian Disease
Rahit, K. M. T. H., & Tarailo-Graovac, M. (2020) · Genes · doi:10.3390/genes11030239 · Cited by 167
“It is evident that with the integration of appropriate genomic assessment, clinicians may provide more accurate patient management [36].”
BackgroundInfluentialSelf-citationNANS-mediated synthesis of sialic acid is required for brain and skeletal development
van Karnebeek, C. D. M., Bonafé, L., Wen, X.-Y., Tarailo-Graovac, M., Balzano, S., Royer-Bertrand, B., Ashikov, A., Garavelli, L., Mammi, I., Turolla, L., et al. (2016) · Nature Genetics · doi:10.1038/ng.3578 · Cited by 164
Self-citationMaione, L., Dwyer, A. A., Francou, B., Guiochon‐Mantel, A., Binart, N., Bouligand, J., & Young, J. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0749 · Cited by 163
Phenotypic expansion illuminates multilocus pathogenic variation
Karaca, E., Posey, J. E., Coban‐Akdemir, Z., Pehlivan, D., Harel, T., Jhangiani, S. N., Bayram, Y., Song, X., Bahrambeigi, V., Yüreğir, Ö. Ö., et al. (2018) · Genetics in Medicine · doi:10.1038/gim.2018.33 · Cited by 158
“18 From a clinical standpoint, recognition of multiple molecular diagnoses can have important implications for both treatment and estimates of familial recurrence risk.”
Debunking Occam's razor: Diagnosing multiple genetic diseases in families by whole‐exome sequencing
Balci, T. B., Hartley, T., Xi, Y., Dyment, D. A., Beaulieu, C. L., Bernier, F. P., Dupuis, L., Horvath, G. A., Mendoza‐Londono, R., Prasad, C., et al. (2017) · Clinical Genetics · doi:10.1111/cge.12987 · Cited by 150
“3% [4 out of 28]) of multiple diagnoses published to date.(16) The suspicion of multiple genetic diagnoses might instinc-”
BackgroundSelf-citationACTB Loss-of-Function Mutations Result in a Pleiotropic Developmental Disorder
Cuvertino, S., Stuart, H. M., Chandler, K. E., Roberts, N. A., Armstrong, R., Bernardini, L., Bhaskar, S., Callewaert, B., Clayton-Smith, J., Davalillo, C. H., et al. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.11.006 · Cited by 135
“Leu110ArgfsTer10 ACTB point mutation in the CAUSES Study by using the analytical pipeline described previously.(8) The procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national), and proper informed consent was obtained.”
MethodSelf-citationSmith, H. S., Swint, J. M., Lalani, S. R., Yamal, J., Otto, M. C. D. O., Castellanos, S., Taylor, A. N., Lee, B., & Russell, H. V. (2018) · Genetics in Medicine · doi:10.1038/s41436-018-0024-6 · Cited by 147
Tebani, A., Abily-Donval, L., Afonso, C., Marret, S., & Bekri, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071167 · Cited by 147
“With this regard, combining genomic and metabolic profiling information to enhance clinical diagnostics and to enable patient stratification and monitoring of interventional pathways patient journeys is a promising field [22,176].”
BackgroundCADmutations and uridine-responsive epileptic encephalopathy
Koch, J., Mayr, J. A., Alhaddad, B., Rauscher, C., Bierau, J., Kovács-Nagy, R., Coene, K. L. M., Bader, I., Holzhacker, M., Prokisch, H., et al. (2016) · Brain · doi:10.1093/brain/aww300 · Cited by 136
Self-citationHuman germline heterozygous gain-of-function STAT6 variants cause severe allergic disease
Sharma, M., Leung, D., Momenilandi, M., Jones, L. C. W., Pacillo, L., James, A. E., Murrell, J. R., Delafontaine, S., Maimaris, J., Vaseghi-Shanjani, M., et al. (2023) · Journal of Experimental Medicine · doi:10.1084/jem.20221755 · Cited by 125
Self-citationFunctional Selectivity in Cytokine Signaling Revealed Through a Pathogenic EPO Mutation
Kim, A. R., Ulirsch, J. C., Wilmes, S., Unal, E., Moraga, I., Karakukcu, M., Yuan, D., Kazerounian, S., Abdulhay, N. J., King, D. S., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.026 · Cited by 114
“This provides a rare example of how whole-exome sequencing and follow-up studies can lead to successful and modified treatment approaches, as has been recently described for specific metabolic disorder cases (Tarailo-Graovac et al., 2016).”
BackgroundLehman, A., Thouta, S., Mancini, G. M. S., Naidu, S., van Slegtenhorst, M., McWalter, K. M., Person, R., Mwenifumbo, J. C., Salvarinova, R., Guella, I., et al. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.05.016 · Cited by 133
Self-citationClinical application of next-generation sequencing to the practice of neurology
Rexach, J. E., Lee, H., Martínez-Agosto, J. A., Nemeth, A. H., & Fogel, B. L. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30033-x · Cited by 126
Palmer, E. E., Schofield, D., Shrestha, R., Kandula, T., Macintosh, R., Lawson, J. A., Andrews, I., Sampaio, H., Johnson, A. M., Farrar, M. A., et al. (2018) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.355 · Cited by 113
Smith, E. D., Radtke, K., Rossi, M., Shinde, D. N., Darabi, S., El‐Khechen, D., Powis, Z., Helbig, K. L., Waller, K., Grange, D. K., et al. (2017) · Human Mutation · doi:10.1002/humu.23183 · Cited by 118
“For some diseases, exome sequencing can even contribute to finding intervention: recently, DES in a cohort of patients with intellectual developmental disorder and unexplained metabolic abnormalities was reported to lead to a change in treatment in 44% of cases [Tarailo-Graovac et al., 2016].”
Genome sequencing and implications for rare disorders
Posey, J. E. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1127-0 · Cited by 129
“Dual molecular diagnoses are now recognized to account for at least 4% of cases for which molecular testing is diagnostic [16–19, 23], with a diagnostic rate that is even higher (12%) in cohorts of selected phenotypes [22] or in cases with apparent phenotypic expansion (32%) [28].”
BackgroundKnowledge base and mini-expert platform for the diagnosis of inborn errors of metabolism
Lee, J. J. Y., Wasserman, W. W., Hoffmann, G. F., van Karnebeek, C. D. M., & Blau, N. (2018) · Genetics in Medicine · doi:10.1038/gim.2017.108 · Cited by 107
Self-citationThe clinical utility of exome and genome sequencing across clinical indications: a systematic review
Shickh, S., Mighton, C. E., Uleryk, E. M., Pechlivanoglou, P., & Bombard, Y. (2021) · Human Genetics · doi:10.1007/s00439-021-02331-x · Cited by 115
Pehlivan, D., Bayram, Y., Güneş, N., Coban‐Akdemir, Z., Shukla, A., Bierhals, T., Tabakci, B., Şahin, Y., Gezdirici, A., Fatih, J. M., et al. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.05.015 · Cited by 119
Species classifier choice is a key consideration when analysing low-complexity food microbiome data
Walsh, A. M., Crispie, F., O’Sullivan, O., Finnegan, L., Claesson, M. J., & Cotter, P. D. (2018) · Microbiome · doi:10.1186/s40168-018-0437-0 · Cited by 98
“In contrast, the higher-throughput Ion Proton, also from Life Technologies, is comparatively overlooked for metagenomic sequencing, whereas it is widely used for exome sequencing analysis of higher organisms [25 – 27].”
Malinowski, J. R., Miller, D. T., Demmer, L., Gannon, J. L., Pereira, E. M., Schroeder, M. C., Scheuner, M. T., Tsai, A. C., Hickey, S. E., & Shen, J. (2020) · Genetics in Medicine · doi:10.1038/s41436-020-0771-z · Cited by 109
Dragojlovic, N., Elliott, A. M., Adam, S., van Karnebeek, C., Lehman, A., Mwenifumbo, J. C., Nelson, T. N., du Souich, C., Friedman, J. M., & Lynd, L. D. (2018) · Genetics in Medicine · doi:10.1038/gim.2017.226 · Cited by 100
Self-citationNetwork analysis reveals rare disease signatures across multiple levels of biological organization
Buphamalai, P., Kokotovic, T., Nagy, V., & Menche, J. (2021) · Nature Communications · doi:10.1038/s41467-021-26674-1 · Cited by 95
“…ROC curves for the performance of causal gene prioritization of our approach (yellow, AUROC = = 0.95) and various gene level based benchmarks (AUROC between 0.59 and 0.87). d Number of patients for which the true causal gene was prioritized among the top fi ve, 10, and 20 for all considered methods.”
BackgroundInfluentialRare genetic diseases: update on diagnosis, treatment and online resources
Pogue, R. E., Cavalcanti, D. P., Shanker, S., de Andrade, R. V., Aguiar, L. R., Carvalho, J. L., & Costa, F. F. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.11.002 · Cited by 115
PLPHP deficiency: clinical, genetic, biochemical, and mechanistic insights
Johnstone, D. L., Al-Shekaili, H. H., Tarailo‐Graovac, M., Wolf, N. I., Ivy, A. S., Demarest, S., Roussel, Y., Čiapaitė, J., van Roermund, C. W. T., Kernohan, K. D., et al. (2018) · Brain · doi:10.1093/brain/awy346 · Cited by 97
“Many of the patients were recruited through international collaboration as part of an ongoing TIDEX neurometabolic gene discovery project (Tarailo-Graovac et al., 2016).”
BackgroundSelf-citationGlutaminase Deficiency Caused by Short Tandem Repeat Expansion in GLS
van Kuilenburg, A. B. P., Tarailo-Graovac, M., Richmond, P. A., Drögemöller, B. I., Pouladi, M. A., Leen, R., Brand-Arzamendi, K., Dobritzsch, D., Dolzhenko, E., Eberle, M. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1806627 · Cited by 91
Self-citationChung, C. C. Y., Hue, S. P. Y., Ng, N. Y. T., Doong, P. H. L., Chu, A. T.-W., & Chung, B. H. (2023) · Genetics in Medicine · doi:10.1016/j.gim.2023.100896 · Cited by 113
Therapeutic role of sirtuins in neurodegenerative disease and their modulation by polyphenols
Ajami, M., Pazoki–Toroudi, H., Amani, H., Nabavi, S. F., Braidy, N., Vacca, R. A., Atanasov, A. G., MOCAN, A., & Nabavi, S. M. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.11.022 · Cited by 100
Rasouly, H. M., Groopman, E., Heyman-Kantor, R., Fasel, D. A., Mitrotti, A., Westland, R., Bier, L., Weng, C., Ren, Z., Copeland, B. R., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m18-1241 · Cited by 95
Bi-allelic GOT2 Mutations Cause a Treatable Malate-Aspartate Shuttle-Related Encephalopathy
van Karnebeek, C., Ramos, R. J. J. F., Wen, X., Tarailo‐Graovac, M., Gleeson, J. G., Skrypnyk, C., Brand‐Arzamendi, K., Karbassi, F., Issa, M. Y., van der Lee, R., et al. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.07.015 · Cited by 87
“The data were further analyzed using our semi-automated bioinformatics pipeline:(11) (1) the duplicates were marked and sorted using Picard, (2) variants were called using SAMtools and BCFtools after indel realignment using GATK, (3) transcripts were annotated using snpEff,(12) (4) functional variants were prioritized…”
MethodSelf-citationClinical utility of genomic analysis in adults with idiopathic liver disease
Hakim, A., Zhang, X., DeLisle, A., Oral, E. A., Dykas, D., Drzewiecki, K., Assis, D. N., Silveira, M., Batisti, J., Jain, D., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.01.036 · Cited by 81
Baer, S., Afenjar, A., Smol, T., Piton, A., Gérard, B., Alembik, Y., Bienvenu, T., Boursier, G., Boute, O., Colson, C., et al. (2018) · Clinical Genetics · doi:10.1111/cge.13254 · Cited by 91
The role of the clinician in the multi‐omics era: are you ready?
van Karnebeek, C., Wortmann, S. B., Tarailo‐Graovac, M., Langeveld, M., Ferreira, C. R., van de Kamp, J. M., Hollak, C. E. M., Wasserman, W. W., Waterham, H. R., Wevers, R. A., et al. (2018) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0128-1 · Cited by 90
Self-citationRapid Whole-Exome Sequencing as a Diagnostic Tool in a Neonatal/Pediatric Intensive Care Unit
Śmigiel, R. S., Biela, M., Szmyd, K., Błoch, M., Szmida, E., Skiba, P., Walczak, A., Gasperowicz, P., Kosińska, J., Rydzanicz, M., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072220 · Cited by 89
Papuc, S. M., Abela, L., Steindl, K., Begemann, A., Simmons, T. L., Schmitt, B., Zweier, M., Oneda, B., Socher, E., Crowther, L. M., et al. (2019) · European Journal of Human Genetics · doi:10.1038/s41431-018-0299-8 · Cited by 75
Tarailo-Graovac, M., Zhu, J. Y. A., Matthews, A., van Karnebeek, C. D. M., & Wasserman, W. W. (2017) · Genetics in Medicine · doi:10.1038/gim.2017.50 · Cited by 73
Self-citationStudy, T. D., Pagnamenta, A. T., Murakami, Y., Taylor, J., Anzilotti, C., Howard, M. F., Miller, V., Johnson, D. S., Tadros, S., Mansour, S., et al. (2017) · European Journal of Human Genetics · doi:10.1038/ejhg.2017.32 · Cited by 90
Stenton, S. L., Kremer, L. S., Kopajtich, R., Ludwig, C., & Prokisch, H. (2019) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12130 · Cited by 83
“Diagnostic yield can increase to over 65% in carefully selected cohorts where novel genetic diagnoses are sought after.(2) The diagnostic shortfall indicates detection evasion of causative variants or detection of variants of uncertain significance (VUS) due to still existing gaps in knowledge.”
BackgroundSphingosine 1-phosphate lyase deficiency causes Charcot-Marie-Tooth neuropathy
Atkinson, D., Glumac, J. N., Asselbergh, B., Ermanoska, B., Blocquel, D., Steiner, R., Estrada‐Cuzcano, A., Peeters, K., Ooms, T., Vriendt, E. D., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003595 · Cited by 72
“Introducing next-generation sequencing into the clinical workup, together with deep phenotyping, will allow identification of such rare neurometabolic patients.(38) Our study illustrates this threshold concept by demonstrating that partial loss of SPL function leads to a noncongenital disorder exclusively affecting pe…”
BackgroundRim, J. H., Kim, S. H., Hwang, I. S., Kwon, S. S., Kim, H. W., Kim, H. W., Cho, M. J., Ko, A., Youn, S. E., Kim, J., et al. (2018) · BMC Medical Genomics · doi:10.1186/s12920-018-0320-7 · Cited by 72
“The benefits of team interpretations of genomic data in rare diseases have been previously emphasized [15].”
Self-citationWang, H., Lu, Y., Dong, X., Lü, G., Cheng, G., Qian, Y., Ni, Q., Zhang, P., Yang, L., Wu, B., et al. (2020) · Human Genetics · doi:10.1007/s00439-019-02103-8 · Cited by 70
Molecular identification in metabolomics using infrared ion spectroscopy
Martens, J. K., Berden, G., van Outersterp, R. E., Kluijtmans, L. A. J., Engelke, U. F. H., van Karnebeek, C., Wevers, R. A., & Oomens, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-03387-4 · Cited by 69
Self-citationKuperberg, M., Lev, D., Blumkin, L., Zerem, A., Ginsberg, M., Linder, I., Carmi, N., Kivity, S., Lerman‐Sagie, T., & Leshinsky‐Silver, E. (2016) · Journal of Child Neurology · doi:10.1177/0883073816664836 · Cited by 72
“Another recent study focusing solely on patients suspected of having diseases of inborn errors of metabolism, reported 68% positive diagnosis using whole exome sequencing.(16) While that is a higher success rate than ours, their population is also significantly different and less heterogynous.”
BackgroundDiagnosing childhood-onset inborn errors of metabolism by next-generation sequencing
Ghosh, A., Schlecht, H., Heptinstall, L., Bassett, J. K., Cartwright, E., Bhaskar, S. S., Urquhart, J. E., Broomfield, A. A., Morris, A. A. M., Jameson, E., et al. (2017) · Archives of Disease in Childhood · doi:10.1136/archdischild-2017-312738 · Cited by 64
“NGS diagnostic yield (27%) is comparable to that of diagnostic fasting (22%) [27].”
ResultSocieties, O. B. O. T. R. S., Borghesi, A., Mencarelli, M. A., Memo, L., Ferrero, G. B., Bartuli, A., Genuardi, M., Stronati, M., Villani, A., Renieri, A., et al. (2017) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-017-0418-0 · Cited by 64
“In adult and pediatric patients, NGS, and specifically WES, has been demonstrated to be able to change the decision-making processes at the bedside, to guide the long-term clinical management, and to affect the prognosis, when actionable conditions are identified [25].”
BackgroundAtypical cerebral palsy: genomics analysis enables precision medicine
Matthews, A., Blydt-Hansen, I., Al-Jabri, B. A., Andersen, J. C., Tarailo‐Graovac, M., Price, M., Selby, K., Demos, M. K., Connolly, M. B., Drögemöller, B. I., et al. (2018) · Genetics in Medicine · doi:10.1038/s41436-018-0376-y · Cited by 64
Self-citation(2020) · Europe PMC (PubMed Central) · Cited by 83
Prenatal DNA Sequencing: Clinical, Counseling, and Diagnostic Laboratory Considerations
Tayoun, A. N. A., Spinner, N. B., Rehm, H. L., Green, R. C., & Bianchi, D. W. (2017) · Prenatal Diagnosis · doi:10.1002/pd.5038 · Cited by 65
“The possibility that a metabolic condition discovered prenatally may lead to rapid and effective treatment in the neonatal intensive care unit (NICU) can be life altering for affected neonates.(48) Accumulation of fetal sequencing data will eventually lead to the proliferation of longitudinal fetal genotype–phenotype…”
BackgroundAshikov, A., Bakar, N. A., Wen, X., Niemeijer, M., Osorio, G. R. P., Brand‐Arzamendi, K., Hasadsri, L., Hansíková, H., Raymond, K., Vicogne, D., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy213 · Cited by 77
Self-citationImpact of clinical exomes in neurodevelopmental and neurometabolic disorders
Evers, C., Staufner, C., Granzow, M., Paramasivam, N., Hinderhofer, K., Kaufmann, L. T., Fischer, C., Thiel, C., Opladen, T., Kotzaeridou, U., et al. (2017) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2017.06.014 · Cited by 60
“Signi fi cant implicationsof ageneticdiagnosisestablished by WES on family planning, medication selection and systemic investigations have also beenreported by other groups [4,6,11,13,14](see Table1).”
InfluentialUnderstanding mutational effects in digenic diseases
Gazzo, A. M., Raimondi, D., Daneels, D., Moreau, Y., Smits, G., Dooren, S. V., & Lenaerts, T. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx557 · Cited by 65
Sialic acid catabolism by N-acetylneuraminate pyruvate lyase is essential for muscle function
Wen, X., Tarailo‐Graovac, M., Brand‐Arzamendi, K., Willems, A. P., Rakić, B., Huijben, K., Silva, A. D., Pan, X., El‐Rass, S., Ng, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122373 · Cited by 60
“multiple inheritance models, as described previously (31).”
Self-citationKrenn, M., Salzer, E., Simonitsch-Klupp, I., Rath, J., Wagner, M., Haack, T. B., Strom, T. M., Schänzer, A., Kilimann, M. W., Schmidt, R. L. J., et al. (2018) · Journal of Neurology · doi:10.1007/s00415-017-8710-x · Cited by 58
A post hoc study on gene panel analysis for the diagnosis of dystonia
van Egmond, M. E., Lugtenberg, C. H. A., Brouwer, O. F., Contarino, M. F., Fung, V. S. C., Heiner-Fokkema, M. R., van Hilten, J. J., van der Hout, A. H., Peall, K. J., Sinke, R. J., et al. (2017) · Movement Disorders · doi:10.1002/mds.26937 · Cited by 57
Santos-Cortez, R. L. P., Khan, V., Khan, F. S., Mughal, Z.-U.-N., Chakchouk, I., Lee, K., Rasheed, M., Hamza, R., Acharya, A., Ullah, E., et al. (2018) · Human Genetics · doi:10.1007/s00439-018-1928-6 · Cited by 55
Uncovering Missing Heritability in Rare Diseases
Maroilley, T., & Tarailo‐Graovac, M. (2019) · Genes · doi:10.3390/genes10040275 · Cited by 64
Self-citationMANAGEMENT OF ENDOCRINE DISEASE: Diagnostic and therapeutic approach of tall stature
Albuquerque, E. V. D. A., Scalco, R. C., & Jorge, A. A. L. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-1054 · Cited by 57
Diagnostic Yields of Trio-WES Accompanied by CNVseq for Rare Neurodevelopmental Disorders
Gao, C., Wang, X., Mei, S., Li, D., Duan, J., Zhang, P., Chen, B., Han, L., Gao, Y., Yang, Z., et al. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00485 · Cited by 63
Prevalence and characteristics of genetic disease in adult kidney stone formers
Anderegg, M. A., Olinger, E. G., Bargagli, M., Geraghty, R. M., Taylor, L., Nater, A., Bruggmann, R., Sayer, J. A., Vogt, B., Schaller, A., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae074 · Cited by 58
“Whole exome sequencing (WES) is widely applied as a diagnostic tool for rare diseases and the detection of pathogenic variants in cancer [15 , 16 ].”
BackgroundGraham, E., Lee, J. K., Price, M., Tarailo‐Graovac, M., Matthews, A., Engelke, U. F. H., Tang, J. S., Kluijtmans, L. A. J., Wevers, R. A., Wasserman, W. W., et al. (2018) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-018-0139-6 · Cited by 56
“…in IEM diagnositics are best illustrated through the exploration of four cases reported in our TIDEX neurometabolic gene discovery study (Tarailo-Graovac et al, 2016), each with a known IEMcausing variant: a CPT1A variant, NANS variant, DYRK1A variant, and SCN2A variant, respectively…”
BackgroundInfluentialSelf-citationAndolfo, I., Martone, S., Rosato, B. E., Marra, R., Gambale, A., Forni, G. L., Pinto, V. M., Göransson, M., Papadopoulou, V., Gavillet, M., et al. (2021) · Genes · doi:10.3390/genes12070958 · Cited by 55
“Indeed, dual molecular diagnoses have been reported to account for at least 4% of diagnosed cases [23], with higher rates seen for case series of selected phenotypes (12%) [24] and for cases with apparent phenotypic expansion (32%) [25].”
BackgroundMelatonin enhances survival and preserves functional integrity of stem cells: A review
Lee, M. S.-S., Yin, T., Sung, P., Chiang, J. Y., Sun, C., & Yip, H. (2016) · Journal of Pineal Research · doi:10.1111/jpi.12372 · Cited by 46
“INTRODUCTION Even in the twenty-first century when refinement of pharmacological therapy [1-6], continuous improvement of the instruments [7-11] and diagnostic techniques [12, 13], advanced skills for treatment interventions [9-11], dedicated protocol for care of hospitalized patients [14, 15], good programs for healt…”
BackgroundTreatment of Neurogenetic Developmental Conditions: From 2016 into the Future
van Karnebeek, C., Bowden, K., & Berry‐Kravis, E. (2016) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2016.07.010 · Cited by 49
Genetic Counseling and Genome Sequencing in Pediatric Rare Disease
Elliott, A. M. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036632 · Cited by 47
Xiao, B., Qiu, W., Ji, X., Liu, X., Huang, Z., Liu, H., Fan, Y., Xu, Y. K., Liu, Y., Yie, H., et al. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38542 · Cited by 42
“…(NGS) is increasingly being employed as a diagnostic tool for Mendelian disorders, which has greatly improved the diagnostic yield to 25–68% (Shashi et al., 2014; Stark et al., 2016; Tarailo-Graovac et al., 2016; Yang et al., 2013), with the highest yield in patients with neurological diseases.”
Integrative omics approaches to advance rare disease diagnostics
Smirnov, D., Konstantinovskiy, N., & Prokisch, H. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12663 · Cited by 49
“Several studies have used untargeted metabolomics to provide additional evidence to confirm the pathogenicity of variants.(17,24,38,114,121,122) The application of metabolite set enrichment analysis on untargeted metabolomics data has also been shown to prioritise relevant pathways for inherited metabolic disorders.”
The cost trajectory of the diagnostic care pathway for children with suspected genetic disorders
Dragojlovic, N., van Karnebeek, C., Ghani, A., Genereaux, D., Kim, E., Birch, P. H., Adam, S., Dragojlovic, N., du Souich, C., Elliott, A. M., et al. (2019) · Genetics in Medicine · doi:10.1038/s41436-019-0635-6 · Cited by 41
Self-citationGauthaman, K., Alfakeeh, S. M., Bahmaid, A. O., Huwait, E. A., Gari, M. A., Abbas, M. M., Ahmed, F., Abu-Elmagd, M. M., & Pushparaj, P. N. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00646 · Cited by 43
Strategies to Uplift Novel Mendelian Gene Discovery for Improved Clinical Outcomes
Seaby, E. G., Rehm, H. L., & O’Donnell‐Luria, A. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.674295 · Cited by 46
Mahler, E. A., Johannsen, J., Tsiakas, K., Kloth, K., Lüttgen, S., Mühlhausen, C., Alhaddad, B., Haack, T. B., Strom, T. M., Kortüm, F., et al. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0197 · Cited by 50
“The success rate of WES has been reported as 25 to 68% and is particularly high when: ● The study group is highly selected (17, 22) ● The exome sequencing is extended to parents (trio exome sequencing) and/or other family members (family exome sequencing) (17, 26) ● The analysis of the exome data embraces all known ge…”
BackgroundChiu, F. P., Doolan, B. J., McGrath, J. A., & Onoufriadis, A. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19384 · Cited by 42
The genotypic and phenotypic spectrum of MTO1 deficiency
O’Byrne, J. J., Tarailo‐Graovac, M., Ghani, A., Champion, M., Deshpande, C., Dursun, A., Özgül, R. K., Freisinger, P., Garber, I., Haack, T. B., et al. (2017) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2017.11.003 · Cited by 39
Self-citationAlmontashiri, N. A. M., Zha, L., Young, K., Law, T., Kellogg, M. D., Bodamer, O. A., & Peake, R. W. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-66401-2 · Cited by 44
Multiomics tools for the diagnosis and treatment of rare neurological disease
Crowther, L. M., Poms, M., & Plecko, B. (2018) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-018-0154-7 · Cited by 41
“…NANS gene (encoding for N-acetylneuraminic acid phosphate synthase) and correlated with increased levels of the NANS substrate N-acetylated mannosamine in urine, plasma, and CSF. Animal models of NANS deficiency were amenable to treatment with N-acetylneuraminic acid (Tarailo-Graovac et al. 2016).”
BackgroundMethodInfluentialGhosh, S. G., Lee, S., Fabunan, R., Chai, G., Zaki, M. S., Abdel‐Salam, G. M. H., Sultan, T., Ben‐Omran, T., Alvi, J. R., McEvoy‐Venneri, J., et al. (2020) · Genetics in Medicine · doi:10.1038/s41436-020-01010-y · Cited by 41
Study, C., Nambot, S., Faivre, L. O., Mirzaa, G., Thévenon, J., Bruel, A., Mosca‐Boidron, A., Masurel, A., Goldenberg, A., Meur, N. L., et al. (2020) · European Journal of Human Genetics · doi:10.1038/s41431-020-0571-6 · Cited by 36
Self-citationSingapore Undiagnosed Disease Program: Genomic Analysis aids Diagnosis and Clinical Management
Bhatia, N. S., Lim, J. Y., Bonnard, C., Kuan, J. L., Brett, M., Wei, H., Cham, B., Chin, H.-L. L., Bosso-Lefèvre, C., Dharuman, P., et al. (2020) · Archives of Disease in Childhood · doi:10.1136/archdischild-2020-319180 · Cited by 40
Neocleous, V., Fanis, P., Toumba, M., Tanteles, G. A., Schiza, M., Cinarli, F., Nicolaides, N. C., Oulas, A., Spyrou, G. M., Mantzoros, C. S., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00626 · Cited by 39
“Over the recent few years, genetic evaluation of patients with inherited diseases, including CHH, has increasingly utilized massive parallel sequencing by next-generation sequencing (NGS), that allows the concurrent investigation of thousands of genes (1, 15, 77).”
BackgroundRepurposing eflornithine to treat a patient with a rare ODC1 gain-of-function variant disease
Rajasekaran, S., Bupp, C. P., Leimanis, M. L., Shukla, A., Russell, C., Junewick, J. J., Gleason, E. G., VanSickle, E., Edgerly, Y. M., Wittmann, B. M., et al. (2021) · eLife · doi:10.7554/elife.67097 · Cited by 34
Exome Sequencing in Clinical Hepatology
Vilarinho, S., & Mistry, P. K. (2019) · Hepatology · doi:10.1002/hep.30826 · Cited by 37
“In 2013, WES of 250 consecutive participants referred for evaluation of a possible genetic condition yielded a genetic diagnosis in a quarter of these patients,(20) and in 2016, deep phenotyping and WES in 41 probands with intellectual developmental disorder and unexplained metabolic abnormalities led to a diagnosis i…”
BackgroundSequencing-based diagnostics for pediatric genetic diseases: progress and potential
Tayoun, A. N. A., Krock, B. L., & Spinner, N. B. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1209411 · Cited by 34
“In a study of 41 probands with intellectual disability and metabolic disorders, diagnoses were made in 68% by exome sequencing, with the possibility of medical intervention based on the underlying medical defect [44].”
Malam, F., Hartley, T., Gillespie, M. K., Armour, C. M., Bariciak, E., Graham, G. E., Nikkel, S. M., Richer, J., Sawyer, S. L., Boycott, K. M., et al. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38250 · Cited by 34
“The relatively high proportion of clinical benefits attributed to a diagnosis was similar to the literature (Tarailo-Graovac et al., 2016).”
Result
Metadata
- Authors
- Tarailo-Graovac, M., Shyr, C., Ross, C. J., Horvath, G. A., Salvarinova, R., Ye, X. C., Zhang, L.-H., Bhavsar, A. P., Lee, J. J. Y., Drögemöller, B. I., Abdelsayed, M., Alfadhel, M., Armstrong, L., Baumgartner, M. R., Burda, P., Connolly, M. B., Cameron, J., Demos, M., Dewan, T., Dionne, J., Evans, A. M., Friedman, J. M., Garber, I., Lewis, S., Ling, J., Mandal, R., Mattman, A., McKinnon, M., Michoulas, A., Metzger, D., Ogunbayo, O. A., Rakic, B., Rozmus, J., Ruben, P., Sayson, B., Santra, S., Schultz, K. R., Selby, K., Shekel, P., Sirrs, S., Skrypnyk, C., Superti-Furga, A., Turvey, S. E., Van Allen, M. I., Wishart, D., Wu, J., Wu, J., Zafeiriou, D., Kluijtmans, L., Wevers, R. A., Eydoux, P., Lehman, A. M., Vallance, H., Stockler-Ipsiroglu, S., Sinclair, G., Wasserman, W. W., & van Karnebeek, C. D.
- Affiliations
- Child and Family Research Institute (CA)
- Simon Fraser University (CA)
- King Saud bin Abdulaziz University for Health Sciences (SA)
- University Children's Hospital Zurich (CH)
- University of Toronto (CA)
- University of Edinburgh (GB)
- The University of Texas Health Science Center at Houston (US)
- University of Alberta (CA)
- Birmingham Children's Hospital (GB)
- University of British Columbia (CA)
- Arabian Gulf University (BH)
- Aristotle University of Thessaloniki (GR)
- Radboud University Medical Center (NL)
- ORCID
- Ross, Colin J.
- Horvath, Gabriella A.
- Salvarinova, Ramona
- Bhavsar, Amit P.
- Drögemöller, Britt I.
- Abdelsayed, Mena
- Alfadhel, Majid
- Armstrong, Linlea
- Baumgartner, Matthias R.
- Connolly, Mary B.
- Cameron, Jessie
- Demos, Michelle
- Dewan, Tammie
- Dionne, Janis
- Friedman, Jan M.
- Ling, Jiqiang
- McKinnon, Margaret
- Metzger, Daniel
- Ogunbayo, Oluseye A.
- Rozmus, Jacob
- Ruben, Peter
- Santra, Saikat
- Schultz, Kirk R.
- Selby, Kathryn
- Sirrs, Sandra
- Skrypnyk, Cristina
- Turvey, Stuart E.
- Wishart, David
- Wu, Jiang
- Wu, John
- Zafeiriou, Dimitrios
- Kluijtmans, Leo
- Wevers, Ron A.
- Lehman, Anna M.
- Vallance, Hilary
- Sinclair, Graham
- Wasserman, Wyeth W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-06-09
- Volume
- 374
- Issue
- 23
- Pages
- 2246-2255
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4983272
- OpenAlex
- W2405784650
- Cited by
- 281
- References
- 83
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 19 · 2023: 17 · 2022: 19 · 2021: 25 · 2020: 35 · 2019: 37 · 2018: 44 · 2017: 44 · 2016: 21
- FWCI
- 48.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- PubMed Central (acceptedVersion)
- Summit (Simon Fraser University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- IRIS (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Genome Canada (ABC4DE)
- Children's Hospital Foundation
- BC Children's Hospital
- Michael Smith Health Research BC
- Genome British Columbia (00032, ABC4DE, SOF195, 301221)
- British Heart Foundation (RG/12/14/29885, 29885)
- University of British Columbia
- Fondation Leenaards
- Canadian Institutes of Health Research (#301221)
- National Institute of General Medical Sciences (GM115431, R01GM115431)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- exome sequencing, neurometabolic disorders, inborn errors of metabolism, intellectual disability, genetic diagnosis, candidate genes, targeted interventions, disease-modifying therapy, genetic counseling
- MeSH terms
- Adolescent, Adult, Child, Child, Preschool, Female, Genetic Testing, Genotype, Humans, Infant, Male, Intellectual Disability, Metabolism, Inborn Errors, Phenotype, Sequence Analysis, DNA, Young Adult, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.